Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy

Yıl: 2020 Cilt: 31 Sayı: 8 Sayfa Aralığı: 588 - 595 Metin Dili: İngilizce DOI: 10.5152/tjg.2020.19114 İndeks Tarihi: 20-05-2021

Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy

Öz:
Background/Aims: Lipodystrophy is a rare metabolic disorder characterized by a near-total or partial lack of subcutaneous adipose tissue and is associated with insulin resistance. We aimed to evaluate the efficacy of magnetic resonance spectroscopy (MRS) imaging to explore the fat content of the liver in patients with lipodystrophy and to determine the relationship between liver fat accumulation and clinical presentations of lipodystrophy. Materials and Methods: Between July 2014 and February 2016, 34 patients with lipodystrophy were assessed by MRS for the quantifi cation of hepatic steatosis. All patients had metabolic abnormalities associated with insulin resistance. Metabolic parameters and the MRS findings were analyzed to identify potential correlations between liver fat content and disease severity. Results: The MRS fat ratios (MRS-FRs) were markedly higher, indicating severe hepatic steatosis in lipodystrophy. Patients with gener alized and partial lipodystrophy had comparable levels of MRS-FRs, although patients with generalized lipodystrophy were significantly younger. Patients with genetic lipodystrophy had elevated MRS-FRs compared with those with acquired lipodystrophy (p=0.042). The MRS-FR was positively correlated with liver enzyme alanine aminotransferase (p=0.028) and serum adiponectin (p=0.043). Conclusion: Our data suggest that MRS might be an effective, non-invasive imaging method to quantify hepatic fat content in patients with lipodystrophy. Further studies are needed to validate the technique and threshold values, which would allow accurate comparison of data acquired by different machines and centers.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Mitchell S. Singular case of absence of adipose matter in the upper half of the body. Am J Med Sci 1885; 90: 2. [Crossref]
  • 2. Berardinelli W. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol Metab 1954; 14: 193-204. [Crossref]
  • 3. Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. QJ Med 1974; 43: 33-48.
  • 4. Kobberling J, Dunnigan MG. Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state. J Med Genet 1986; 23: 120-7. [Crossref]
  • 5. Akinci B, Meral R, Oral EA. Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities. Curr Diab Rep 2018; 18: 143. [Crossref]
  • 6. Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011; 96: 3313-25. [Crossref]
  • 7. Altay C, Secil M, Demir T, Atik T, Akinci G. Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy. Diagn Interv Radiol 2017: 428-34. [Crossref]
  • 8. Hussain I, Patni N, Ueda M, et al. A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation. J Clin Endocrinol Metab 2018; 103: 1005-14. [Crossref]
  • 9. Mory PB, Crispim F, Kasamatsu T, Gabbay MA, Dib SA, Moises RS. Atypical generalized lipoatrophy and severe insulin resistance due to a heterozygous LMNA p.T10I mutation. Arq Bras Endocrinol Metabol 2008; 52: 1252-6. [Crossref]
  • 10. Patni N, Xing C, Agarwal AK, Garg A. Juvenile-onset generalized lipodystrophy due to a novel heterozygous missense LMNA mutation affecting lamin C. Am J Med Genet A 2017; 173: 2517-21. [Crossref]
  • 11. Montenegro RM, Jr., Costa-Riquetto AD, Fernandes VO, et al. Homozygous and Heterozygous Nuclear Lamin A p.R582C Mutation: Different Lipodystrophic Phenotypes in the Same Kindred. Front Endocrinol (Lausanne) 2018; 9: 458. [Crossref]
  • 12. Simha V, Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 2006; 17: 162-9. [Crossref]
  • 13. Akinci B, Onay H, Demir T, et al. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy. Metabolism 2017; 72: 109-19. [Crossref]
  • 14. Ajluni N, Meral R, Neidert AH, et al. Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clin Endocrinol (Oxf) 2017; 86: 698-707. [Crossref]
  • 15. Akinci B, Koseoglu FD, Onay H, et al. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metabolism 2015; 64: 1086-95. [Crossref]
  • 16. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) 2003; 82: 129-46. [Crossref]
  • 17. Garg A, Misra A. Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 2004; 33: 305-31. [Crossref]
  • 18. Akinci B, Sahinoz M, Oral E. Lipodystrophy Syndromes: Presentation and Treatment. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al., editors. Endotext. South Dartmouth (MA) 2000.
  • 19. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab 2016; 101: 4500-11. [Crossref]
  • 20. Bamber J, Cosgrove D, Dietrich CF, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. Ultraschall Med 2013; 34: 169-84. [Crossref]
  • 21. Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: clinical applications. J Comput Assist Tomogr 2013; 37: 887-96. [Crossref]
  • 22. Georgoff P, Thomasson D, Louie A, et al. Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. AJR Am J Roentgenol 2012; 199: 2-7. [Crossref]
  • 23. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994; 12: 487-95. [Crossref]
  • 24. Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011; 21: 87-97. [Crossref]
  • 25. Verma A, Kumar I, Verma N, Aggarwal P, Ojha R. Magnetic resonance spectroscopy - Revisiting the biochemical and molecular milieu of brain tumors. BBA Clin 2016; 5: 170-8. [Crossref]
  • 26. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-8. [Crossref]
  • 27. Weijers G, Wanten G, Thijssen JM, van der Graaf M, de Korte CL. Quantitative Ultrasound for Staging of Hepatic Steatosis in Patients on Home Parenteral Nutrition Validated with Magnetic Resonance Spectroscopy: A Feasibility Study. Ultrasound Med Biol 2016; 42: 637-44. [Crossref]
  • 28. Akinci B, Onay H, Demir T, et al. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study from Turkey. J Clin Endocrinol Metab 2016; 101: 2759-67. [Crossref]
  • 29. Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes 2017; 10: 375-83. [Crossref]
  • 30. Bannas P, Kramer H, Hernando D, et al. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers. Hepatology 2015; 62: 1444-55. [Crossref]
  • 31. Idilman IS, Keskin O, Celik A, et al. A comparison of liver fat content as determined by magnetic resonance imaging-proton densifat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiol 2016; 57: 271-8. [Crossref]
  • 32. Hwang I, Lee JM, Lee KB, et al. Hepatic steatosis in living liver donor candidates: preoperative assessment by using breath-hold triple-echo MR imaging and 1H MR spectroscopy. Radiology 2014; 271: 730-8. [Crossref]
  • 33. Idilman IS, Aniktar H, Idilman R, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013; 267: 767-75. [Crossref]
  • 34. Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013; 267: 422-31. [Crossref]
  • 35. Hadigan C, Liebau J, Andersen R, Holalkere NS, Sahani DV. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr 2007; 46: 312-7. [Crossref]
  • 36. Ghotb A, Noworolski SM, Madden E, et al. Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy. J Acquir Immune Defic Syndr 2010; 55: 228-31. [Crossref]
  • 37. Vu KN, Gilbert G, Chalut M, Chagnon M, Chartrand G, Tang A. MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes. J Magn Reson Imaging 2016; 43: 1090-9. [Crossref]
  • 38. Kim JH, Chang KH, Na DG, et al. Comparison of 1.5T and 3T 1H MR spectroscopy for human brain tumors. Korean J Radiol 2006; 7: 156-61. [Crossref]
  • 39. Koplay M, Sivri M, Erdogan H, Nayman A. Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. World J Hepatol 2015; 7: 769-76. [Crossref]
  • 40. Merkle EM, Nelson RC. Dual gradient-echo in-phase and opposed-phase hepatic MR imaging: a useful tool for evaluating more than fatty infiltration or fatty sparing. Radiographics 2006; 26: 1409-18. [Crossref]
APA ALTAY C, SEÇIL M, Adiyaman S, Ozgen Saydam B, DEMIR T, Akinci G, YILDIRIM SIMSIR I, Eren E, keskin f, DEMİR L, Onay H, Topaloglu H, sarer yurekli b, Ozdemir N, Gen R, Akinci B (2020). Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. , 588 - 595. 10.5152/tjg.2020.19114
Chicago ALTAY CANAN,SEÇIL MUSTAFA,Adiyaman Suleyman Cem,Ozgen Saydam Basak,DEMIR TEVFIK,Akinci Gulcin,YILDIRIM SIMSIR ILGIN,Eren Erdal,keskin fatma Ela,DEMİR LEYLA,Onay Huseyin,Topaloglu Haluk,sarer yurekli banu,Ozdemir Nilufer,Gen Ramazan,Akinci Baris Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. (2020): 588 - 595. 10.5152/tjg.2020.19114
MLA ALTAY CANAN,SEÇIL MUSTAFA,Adiyaman Suleyman Cem,Ozgen Saydam Basak,DEMIR TEVFIK,Akinci Gulcin,YILDIRIM SIMSIR ILGIN,Eren Erdal,keskin fatma Ela,DEMİR LEYLA,Onay Huseyin,Topaloglu Haluk,sarer yurekli banu,Ozdemir Nilufer,Gen Ramazan,Akinci Baris Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. , 2020, ss.588 - 595. 10.5152/tjg.2020.19114
AMA ALTAY C,SEÇIL M,Adiyaman S,Ozgen Saydam B,DEMIR T,Akinci G,YILDIRIM SIMSIR I,Eren E,keskin f,DEMİR L,Onay H,Topaloglu H,sarer yurekli b,Ozdemir N,Gen R,Akinci B Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. . 2020; 588 - 595. 10.5152/tjg.2020.19114
Vancouver ALTAY C,SEÇIL M,Adiyaman S,Ozgen Saydam B,DEMIR T,Akinci G,YILDIRIM SIMSIR I,Eren E,keskin f,DEMİR L,Onay H,Topaloglu H,sarer yurekli b,Ozdemir N,Gen R,Akinci B Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. . 2020; 588 - 595. 10.5152/tjg.2020.19114
IEEE ALTAY C,SEÇIL M,Adiyaman S,Ozgen Saydam B,DEMIR T,Akinci G,YILDIRIM SIMSIR I,Eren E,keskin f,DEMİR L,Onay H,Topaloglu H,sarer yurekli b,Ozdemir N,Gen R,Akinci B "Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy." , ss.588 - 595, 2020. 10.5152/tjg.2020.19114
ISNAD ALTAY, CANAN vd. "Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy". (2020), 588-595. https://doi.org/10.5152/tjg.2020.19114
APA ALTAY C, SEÇIL M, Adiyaman S, Ozgen Saydam B, DEMIR T, Akinci G, YILDIRIM SIMSIR I, Eren E, keskin f, DEMİR L, Onay H, Topaloglu H, sarer yurekli b, Ozdemir N, Gen R, Akinci B (2020). Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. Turkish Journal of Gastroenterology, 31(8), 588 - 595. 10.5152/tjg.2020.19114
Chicago ALTAY CANAN,SEÇIL MUSTAFA,Adiyaman Suleyman Cem,Ozgen Saydam Basak,DEMIR TEVFIK,Akinci Gulcin,YILDIRIM SIMSIR ILGIN,Eren Erdal,keskin fatma Ela,DEMİR LEYLA,Onay Huseyin,Topaloglu Haluk,sarer yurekli banu,Ozdemir Nilufer,Gen Ramazan,Akinci Baris Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. Turkish Journal of Gastroenterology 31, no.8 (2020): 588 - 595. 10.5152/tjg.2020.19114
MLA ALTAY CANAN,SEÇIL MUSTAFA,Adiyaman Suleyman Cem,Ozgen Saydam Basak,DEMIR TEVFIK,Akinci Gulcin,YILDIRIM SIMSIR ILGIN,Eren Erdal,keskin fatma Ela,DEMİR LEYLA,Onay Huseyin,Topaloglu Haluk,sarer yurekli banu,Ozdemir Nilufer,Gen Ramazan,Akinci Baris Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. Turkish Journal of Gastroenterology, vol.31, no.8, 2020, ss.588 - 595. 10.5152/tjg.2020.19114
AMA ALTAY C,SEÇIL M,Adiyaman S,Ozgen Saydam B,DEMIR T,Akinci G,YILDIRIM SIMSIR I,Eren E,keskin f,DEMİR L,Onay H,Topaloglu H,sarer yurekli b,Ozdemir N,Gen R,Akinci B Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. Turkish Journal of Gastroenterology. 2020; 31(8): 588 - 595. 10.5152/tjg.2020.19114
Vancouver ALTAY C,SEÇIL M,Adiyaman S,Ozgen Saydam B,DEMIR T,Akinci G,YILDIRIM SIMSIR I,Eren E,keskin f,DEMİR L,Onay H,Topaloglu H,sarer yurekli b,Ozdemir N,Gen R,Akinci B Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. Turkish Journal of Gastroenterology. 2020; 31(8): 588 - 595. 10.5152/tjg.2020.19114
IEEE ALTAY C,SEÇIL M,Adiyaman S,Ozgen Saydam B,DEMIR T,Akinci G,YILDIRIM SIMSIR I,Eren E,keskin f,DEMİR L,Onay H,Topaloglu H,sarer yurekli b,Ozdemir N,Gen R,Akinci B "Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy." Turkish Journal of Gastroenterology, 31, ss.588 - 595, 2020. 10.5152/tjg.2020.19114
ISNAD ALTAY, CANAN vd. "Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy". Turkish Journal of Gastroenterology 31/8 (2020), 588-595. https://doi.org/10.5152/tjg.2020.19114